EQS-Adhoc 117 0 Kommentare SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes

Für Sie zusammengefasst

SCHOTT Pharma AG sees slower growth in FY 25 due to syringes.
Revenue growth forecast for FY 2024/2025 deviates from market consensus.
Lower demand from a large customer affects EBITDA margin expansion.

Foto: Martin Schutt - picture alliance/dpa/dpa-Zentralbild

EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast
SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes

14-May-2024 / 18:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

SCHOTT Pharma see FY 25 impacted by slower growth from syringes

Long

27,81€

Basispreis

0,32

Ask

× 9,44

Hebel

Zum Produkt

Short

33,61€

Basispreis

0,33

Ask

× 9,16

Hebel

Zum Produkt

Präsentiert von

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

For its fiscal year 2024/2025, beginning 1^st October 2024, the company is forecasting a revenue growth in a high single-digit to a low double-digit percentage range, which deviates from the current market consensus. Due to the revenue growth that is lower than previously expected, the EBITDA margin expansion will be weaker than currently expected in the market.

These forecasts are based on constant currencies.

The reason for the expected development in fiscal year 2024/2025 is a lower demand for syringes of a large customer.

Despite this temporary effect, the company confirms its mid-term forecast. The company also confirms its forecast for the current fiscal year.

Investor contact

Jasko Terzic, CFA

Senior Investor Relations Manager

E-Mail: ir.pharma@schott.com

Press contact

Joana Kornblum

Media Relations

Tel.: +49 151/29223552

E-Mail: joana.kornblum@schott.com

End of Inside Information

14-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	SCHOTT Pharma AG & Co. KGaA
	Hattenbergstraße 10
	55122 Mainz
	Germany
ISIN:	DE000A3ENQ51
WKN:	A3ENQ5
Indices:	SDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
EQS News ID:	1902981